Annual EBITDA
-$26.82 M
+$24.17 M+47.40%
December 31, 2023
Summary
- As of February 12, 2025, QNCX annual EBITDA is -$26.82 million, with the most recent change of +$24.17 million (+47.40%) on December 31, 2023.
- During the last 3 years, QNCX annual EBITDA has risen by +$51.74 million (+65.86%).
- QNCX annual EBITDA is now -154.29% below its all-time high of -$10.55 million, reached on December 31, 2017.
Performance
QNCX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$8.46 M
+$338.00 K+3.84%
September 30, 2024
Summary
- As of February 12, 2025, QNCX quarterly EBITDA is -$8.46 million, with the most recent change of +$338.00 thousand (+3.84%) on September 30, 2024.
- Over the past year, QNCX quarterly EBITDA has dropped by -$421.00 thousand (-5.24%).
- QNCX quarterly EBITDA is now -236.92% below its all-time high of -$2.51 million, reached on September 30, 2018.
Performance
QNCX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$33.93 M
-$2.37 M-7.50%
September 30, 2024
Summary
- As of February 12, 2025, QNCX TTM EBITDA is -$33.93 million, with the most recent change of -$2.37 million (-7.50%) on September 30, 2024.
- Over the past year, QNCX TTM EBITDA has dropped by -$7.17 million (-26.82%).
- QNCX TTM EBITDA is now -1124.91% below its all-time high of -$2.77 million, reached on March 31, 2018.
Performance
QNCX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
QNCX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +47.4% | -5.2% | -26.8% |
| 3 y3 years | +65.9% | -5.2% | -26.8% |
| 5 y5 years | -133.9% | -5.2% | -26.8% |
QNCX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +70.2% | -51.5% | +63.9% | -35.8% | +62.3% |
| 5 y | 5-year | at high | +70.2% | -51.5% | +63.9% | -35.8% | +62.3% |
| alltime | all time | -154.3% | +70.2% | -236.9% | +63.9% | -1124.9% | +62.3% |
Quince Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$8.46 M(-3.8%) | -$33.93 M(+7.5%) |
| Jun 2024 | - | -$8.80 M(+1.9%) | -$31.56 M(+11.3%) |
| Mar 2024 | - | -$8.63 M(+7.4%) | -$28.35 M(+6.0%) |
| Dec 2023 | -$26.82 M(-47.4%) | -$8.04 M(+31.9%) | -$26.75 M(+7.0%) |
| Sep 2023 | - | -$6.09 M(+9.2%) | -$24.99 M(-2.6%) |
| Jun 2023 | - | -$5.58 M(-20.7%) | -$25.65 M(-29.2%) |
| Mar 2023 | - | -$7.04 M(+12.1%) | -$36.24 M(-29.0%) |
| Dec 2022 | -$50.99 M(-43.3%) | -$6.28 M(-7.1%) | -$51.03 M(-25.2%) |
| Sep 2022 | - | -$6.75 M(-58.2%) | -$68.21 M(-17.9%) |
| Jun 2022 | - | -$16.17 M(-25.9%) | -$83.05 M(-6.2%) |
| Mar 2022 | - | -$21.82 M(-7.0%) | -$88.57 M(-1.6%) |
| Dec 2021 | -$89.97 M | -$23.46 M(+8.7%) | -$89.97 M(+3.1%) |
| Sep 2021 | - | -$21.59 M(-0.5%) | -$87.28 M(-0.3%) |
| Jun 2021 | - | -$21.70 M(-6.6%) | -$87.52 M(+4.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$23.23 M(+11.8%) | -$84.01 M(+6.9%) |
| Dec 2020 | -$78.56 M(+101.5%) | -$20.77 M(-4.9%) | -$78.56 M(+11.2%) |
| Sep 2020 | - | -$21.83 M(+20.0%) | -$70.67 M(+19.1%) |
| Jun 2020 | - | -$18.19 M(+2.3%) | -$59.35 M(+17.1%) |
| Mar 2020 | - | -$17.77 M(+38.1%) | -$50.70 M(+30.1%) |
| Dec 2019 | -$38.98 M(+239.9%) | -$12.87 M(+22.5%) | -$38.98 M(+31.9%) |
| Sep 2019 | - | -$10.51 M(+10.2%) | -$29.55 M(+37.1%) |
| Jun 2019 | - | -$9.54 M(+57.5%) | -$21.55 M(+46.1%) |
| Mar 2019 | - | -$6.06 M(+75.7%) | -$14.75 M(+28.7%) |
| Dec 2018 | -$11.47 M(+8.7%) | -$3.45 M(+37.2%) | -$11.47 M(+43.0%) |
| Sep 2018 | - | -$2.51 M(-8.4%) | -$8.02 M(+45.6%) |
| Jun 2018 | - | -$2.74 M(-1.0%) | -$5.51 M(+99.0%) |
| Mar 2018 | - | -$2.77 M | -$2.77 M |
| Dec 2017 | -$10.55 M | - | - |
FAQ
- What is Quince Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Quince Therapeutics?
- What is Quince Therapeutics annual EBITDA year-on-year change?
- What is Quince Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Quince Therapeutics?
- What is Quince Therapeutics quarterly EBITDA year-on-year change?
- What is Quince Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Quince Therapeutics?
- What is Quince Therapeutics TTM EBITDA year-on-year change?
What is Quince Therapeutics annual EBITDA?
The current annual EBITDA of QNCX is -$26.82 M
What is the all time high annual EBITDA for Quince Therapeutics?
Quince Therapeutics all-time high annual EBITDA is -$10.55 M
What is Quince Therapeutics annual EBITDA year-on-year change?
Over the past year, QNCX annual EBITDA has changed by +$24.17 M (+47.40%)
What is Quince Therapeutics quarterly EBITDA?
The current quarterly EBITDA of QNCX is -$8.46 M
What is the all time high quarterly EBITDA for Quince Therapeutics?
Quince Therapeutics all-time high quarterly EBITDA is -$2.51 M
What is Quince Therapeutics quarterly EBITDA year-on-year change?
Over the past year, QNCX quarterly EBITDA has changed by -$421.00 K (-5.24%)
What is Quince Therapeutics TTM EBITDA?
The current TTM EBITDA of QNCX is -$33.93 M
What is the all time high TTM EBITDA for Quince Therapeutics?
Quince Therapeutics all-time high TTM EBITDA is -$2.77 M
What is Quince Therapeutics TTM EBITDA year-on-year change?
Over the past year, QNCX TTM EBITDA has changed by -$7.17 M (-26.82%)